Diamond Biotechnology Co (ROCO:6815) EBIT : NT$92.1 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Diamond Biotechnology Co EBIT?

Diamond Biotechnology Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$67.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$92.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Diamond Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2024 was 18.38%. Diamond Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 21.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Diamond Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 4.39%.

Diamond Biotechnology Co EBIT Historical Data

The historical data trend for Diamond Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamond Biotechnology Co EBIT Chart

Diamond Biotechnology Co Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

57.68

15.98

54.32

45.56

65.85

Diamond Biotechnology Co Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial								23.33	22.23	40.94	24.91	67.23

Competitive Comparison of Diamond Biotechnology Co's EBIT

For the Medical Devices subindustry, Diamond Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamond Biotechnology Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Diamond Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Diamond Biotechnology Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Diamond Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$92.1 Mil.

Diamond Biotechnology Co (ROCO:6815) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Diamond Biotechnology Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	157.872 * ( 1 - 20.51% )	/	( (636.799	+	728.727)	/ 2 )
=	125.4924528	/	682.763
=	18.38 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	798.914	-	83.6	-	( 78.515	-	max(0, 265.827	-	397.437	+	78.515	))
=	636.799

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1041.447	-	88.578	-	( 224.142	-	max(0, 231.805	-	673.265	+	224.142	))
=	728.727

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Diamond Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	134.456	/	( ( (375.308 + max(211.746, 0))	+	(349.842 + max(297.172, 0)) )	/	2 )
=	134.456	/	( ( 587.054	+	647.014 )	/	2 )
=	134.456	/	617.034
=	21.79 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(191.425	+	78.278	+	40.912)	-	(83.6	+	0	+	15.269)
=	211.746

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(250.606	+	87.606	+	77.362)	-	(88.578	+	0	+	29.824)
=	297.172

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Diamond Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	92.136	/	2100.459
	=	4.39 %

Diamond Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Diamond Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamond Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Diamond Biotechnology Co Ltd (ROCO:6815) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 45, Section 2, Fuxing South Road, Da'an District, 11th Floor, Taipei, TWN

Website

http://www.diamond-biotechnology.com

Diamond Biotechnology Co Ltd is engaged in the research and development of medical equipment, and medical consumables. It also manufactures and sells medical beauty-level skincare products.

Diamond Biotechnology Co Headlines

No Headlines